CMS and the Medicare private drug plans are using Medicare enrollment to teach seniors -- and their adult advisors -- about the cost savings from therapeutic interchange. Training patients to look for cost savings and to discuss costs with doctors is clearly a secondary objective of the Medicare enrollment process. The Medicare plan finder website and private plan sites carry frequent messages to alert beneficiaries cost savings. Pfizer responds with consumer-based pricing for Lipitor.
Cole Werble
School started Nov. 15 for an accelerated course in pharmaceutical pricing and product switching.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Average sales prices, and Medicare spending on some drugs, would be expected to be lower, CMS says in the Physician Fee Schedule proposed rule.
Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.
Bristol Myers Squibb’s Opdivo and Merck's Welireg also could benefit from the delay in Medicare price negotiation process eligibility.
Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.
PharmaMar has voluntarily withdrawn its marketing authorization application for Aplidin to treat multiple myeloma in the EU – almost a decade after it first filed the drug for EU approval and following years of court proceedings.
Antibiotics that tackle antimicrobial resistance are to be automatically included in Italy’s Innovative Medicines Fund, which is designed to provide quick access to innovative medicines.
The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.
